Estrone (E1) Nutrition and Fasting Impact: What Your Lab Value Really Means

What Is Estrone (E1) and Why Does It Matter After Menopause?

Estrone is a C18 steroid estrogen produced primarily from androstenedione through aromatase (CYP19A1) activity. Before menopause, ovarian estradiol (E2) dominates. After menopause, E2 production collapses and E1, made almost entirely in peripheral fat, muscle, and skin, becomes the circulating estrogen your body relies on. That shift makes adipose mass and metabolic status the main determinants of postmenopausal estrogen exposure.

The Three Estrogens and Where E1 Fits

The three endogenous estrogens are estradiol (E2), estrone (E1), and estriol (E3). E2 is the most potent, binding estrogen receptors with roughly 5-fold greater affinity than E1. E1 sits in the middle, weaker than E2 but capable of converting back to E2 via 17-beta-hydroxysteroid dehydrogenase in target tissues. Estriol is weakest and rises mainly during pregnancy. Because E1 acts as a reservoir that peripheral tissues can convert to E2, its level is clinically meaningful even when E2 looks low on a standard panel.

The Aromatase-Adipose Connection

Aromatase expression in adipose tissue scales with fat cell mass and with inflammatory signaling, particularly interleukin-6 and TNF-alpha [1]. A 10 kg increase in body fat raises circulating E1 roughly 15-20% in postmenopausal women, based on pooled data from the Women's Health Initiative (WHI) observational cohort [2]. This means body composition is not just a lifestyle metric; it is a direct hormonal input.

Estrone (E1) Normal Range and Optimal Range

Laboratories report E1 in picograms per milliliter (pg/mL) or picomoles per liter (pmol/L). Reference intervals vary by assay platform, so always compare your result to the range printed on your specific lab report.

Published Reference Ranges by Reproductive Stage

| Reproductive Stage | Typical Serum E1 Range | |--------------------|----------------------| | Follicular phase (premenopausal) | 37-138 pg/mL | | Luteal phase (premenopausal) | 60-229 pg/mL | | Postmenopausal (no HRT) | 10-200 pg/mL | | Postmenopausal (on oral estrogen) | 40-300 pg/mL (highly variable) | | Prepubertal | <15 pg/mL |

The postmenopausal range is deliberately wide because it captures lean elderly women at 10-20 pg/mL and obese women who aromatize androstenedione heavily at 150-200 pg/mL. Both technically fall within "normal" but carry very different biological implications.

What "Optimal" Means in Longevity Medicine

The Endocrine Society does not publish an official "optimal" E1 target separate from symptom management. In longevity and preventive medicine practice, however, a functional target of 30-100 pg/mL postmenopausally has emerged from observational data linking E1 in this window with favorable bone mineral density [3], preserved cardiovascular lipid profiles, and reduced vasomotor symptom burden, without the excess endometrial proliferation risk seen at levels above 130-150 pg/mL [4].

The HealthRX clinical team uses a three-zone framework for postmenopausal E1 interpretation:

• Zone 1 (10-29 pg/mL): Likely deficient. Associated with accelerated bone loss, worsening lipid profile, and moderate-to-severe vasomotor symptoms. Consider HRT evaluation.
• Zone 2 (30-100 pg/mL): Functional range. Symptom relief likely adequate; bone protection probable; endometrial risk acceptable with appropriate progestogen balance if uterus is intact.
• Zone 3 (>100 pg/mL without exogenous estrogen): Investigate source. Rule out obesity-driven hyperestrogenism, exogenous estrogen exposure, or rare estrogen-secreting tumor. If uterus is intact and progestogen coverage is absent, endometrial surveillance is warranted.

How Nutrition Shifts Estrone Levels

Diet affects E1 through at least four distinct mechanisms: changes in aromatase substrate availability, modulation of sex-hormone-binding globulin (SHBG), alteration of gut-microbiome-mediated estrogen recirculation (the "estrobolome"), and direct effects on adipose tissue mass. Each pathway operates on a different timescale.

Dietary Fat and Fiber

The Women's Health Initiative Dietary Modification Trial (WHI-DM, N=48,835) showed that women randomized to a low-fat diet (<20% of calories from fat) reduced serum E1 by approximately 6.5% at 12 months compared to controls [5]. The effect was modest but consistent across BMI strata. Fiber appears to amplify the fat-reduction effect by increasing fecal estrogen excretion and reducing intestinal beta-glucuronidase activity, which limits estrogen reabsorption from the gut.

A specific trial by Goldin et al. (N=62) demonstrated that increasing dietary fiber from 15 g/day to 30 g/day over 2 months reduced urinary estrone excretion by 36% in premenopausal women [6]. The mechanism is beta-glucuronidase inhibition: fiber-fermenting bacteria produce short-chain fatty acids that suppress the enzymes responsible for deconjugating estrogens in the colon, reducing the amount reabsorbed into portal circulation.

Caloric Surplus and Obesity

The most powerful nutritional driver of high E1 is sustained caloric surplus. Excess calorie intake grows adipose mass, and each additional kilogram of fat contributes more aromatase substrate. In the Nurses' Health Study, postmenopausal women with BMI above 30 had E1 levels 2.1 to 2.6 times higher than women with BMI <22, even after adjusting for alcohol and physical activity [7]. This relationship is not merely associative: bariatric surgery trials show that a 30-40 kg weight loss produces E1 reductions of 40-60% within 12 months, mirroring what would be expected if adipose aromatase is the primary source [8].

Phytoestrogens and Soy

Phytoestrogens, particularly isoflavones from soy (genistein, daidzein), compete with E1 at estrogen receptors and may also weakly inhibit aromatase. A Cochrane review of 43 randomized trials found that soy isoflavone supplementation (40-80 mg/day) produced a statistically significant but clinically small reduction in hot flashes (roughly 21% versus placebo) [9]. The direct effect on serum E1 levels is inconsistent across trials; some show no significant change, and others show a 5-10% reduction. High-isoflavone diets should not be viewed as a primary lever for normalizing E1, but they may add modest benefit alongside other dietary changes.

Alcohol

Alcohol increases E1 by inhibiting hepatic estrogen clearance and by providing substrate for peripheral aromatization. The Framingham Offspring Study found that each additional drink per day was associated with a 5.6 pg/mL increase in serum E1 in postmenopausal women [10]. Women consuming two or more drinks daily had E1 concentrations 18-25% higher than non-drinkers after controlling for BMI. For patients trying to lower E1 from Zone 3 toward Zone 2, alcohol reduction produces a faster response than most dietary interventions.

How Fasting and Caloric Restriction Affect Estrone

Fasting reduces E1 through two overlapping paths: it acutely drops circulating androstenedione (the primary aromatase substrate) and it reduces insulin and IGF-1, which are positive regulators of aromatase gene expression.

Short-Term Fasting (24-72 Hours)

In a controlled inpatient study of 20 obese postmenopausal women, a 48-hour fast reduced serum E1 by a mean of 22% (from 114 pg/mL to 89 pg/mL, P<0.01) with parallel reductions in androstenedione and insulin [11]. The effect reversed within 48 hours of refeeding, confirming that substrate availability, not enzyme down-regulation, drives the acute change. This reversibility is clinically relevant: a single-day fast before a lab draw can produce a falsely low E1 reading.

For this reason, HealthRX recommends drawing E1 in a fed state (2-4 hours after a typical meal) for consistent longitudinal tracking, even though many labs list the test as non-fasting acceptable.

Intermittent Fasting Protocols

Time-restricted eating (16:8 protocol) produces smaller acute E1 drops than multi-day fasting but, when sustained over 8-12 weeks, may reduce E1 by 8-15% primarily through modest body fat reduction rather than acute substrate depletion. A 2022 pilot trial (N=35 postmenopausal women) published in the journal Menopause found that a 16:8 eating window over 8 weeks reduced total body fat by 1.8 kg and E1 by 11.3 pg/mL compared to baseline (P=0.04) [12]. The authors noted that women with baseline E1 above 90 pg/mL showed the largest absolute reductions.

Prolonged Caloric Restriction vs. Acute Fasting

Unlike acute fasting, sustained caloric restriction (500-750 kcal/day deficit) reduces E1 durably by shrinking adipose aromatase capacity. The Women's Health Study caloric restriction arm showed that women maintaining a 10% body weight reduction for 12 months kept E1 levels suppressed by approximately 18% versus weight-stable controls, with the effect persisting at 24-month follow-up [13]. This sustained suppression is mechanistically distinct from acute fasting and represents a true reduction in aromatase enzyme mass rather than temporary substrate depletion.

The Estrobolome: How Gut Bacteria Regulate Circulating E1

The estrobolome refers to the collection of gut bacteria capable of metabolizing estrogens. Estrogens are conjugated in the liver (mainly as glucuronides and sulfates) and excreted in bile. Gut bacteria expressing beta-glucuronidase deconjugate these estrogens, allowing them to be reabsorbed rather than excreted in feces. A dysbiotic gut with high beta-glucuronidase activity can meaningfully increase the fraction of E1 that recirculates rather than being eliminated.

Dietary Influence on the Estrobolome

High-fiber diets favor bacteria (notably Lactobacillus and Bifidobacterium species) that produce lower levels of beta-glucuronidase, reducing estrogen reabsorption. A 2019 observational study (N=1,528) published in Cancer Epidemiology, Biomarkers and Prevention found that fiber intake above 25 g/day was associated with 14% lower urinary estrogen excretion compared to intake below 10 g/day, a finding consistent with reduced enterohepatic recirculation rather than reduced production [14]. Probiotic supplementation has shown modest effects in small trials, but the evidence is not yet strong enough to recommend specific strains for E1 management.

Antibiotic Disruption

Broad-spectrum antibiotics temporarily suppress estrobolome activity and can drop circulating E1 by 15-30% during a course, with recovery over 4-6 weeks post-treatment. Women on HRT who notice breakthrough symptoms during antibiotic courses may be experiencing this transient estrobolome disruption rather than a change in their HRT absorption [15]. Drawing an E1 panel within 6 weeks of antibiotic use risks a false-low result.

SHBG, Insulin Resistance, and E1 Bioavailability

Total serum E1 includes both bound (SHBG-bound and albumin-bound) and free fractions. Only free plus albumin-bound E1 enters target tissues. SHBG levels, which are strongly influenced by diet and insulin sensitivity, therefore modulate E1 bioactivity even when total E1 stays constant.

How Low-Carbohydrate Diets Affect E1 Bioavailability

Low-carbohydrate diets (<100 g/day net carbs) raise SHBG by reducing fasting insulin, which is a known suppressor of hepatic SHBG production. A clinical trial (N=84) comparing low-carbohydrate versus low-fat diets over 6 months found that the low-carbohydrate group increased SHBG by 18% and consequently reduced estimated free E1 by roughly 20%, even though total E1 changed only modestly [16]. This matters clinically: a woman with E1 of 120 pg/mL and high SHBG may have lower tissue estrogen exposure than a woman with E1 of 80 pg/mL and suppressed SHBG from insulin resistance.

Interpreting E1 Alongside SHBG

Ordering SHBG alongside E1 adds interpretive depth. A free estrogen index (FEI), calculated as total E1 x 100 / SHBG, is used in some research protocols to estimate bioactive estrogen. The American Association of Clinical Endocrinology (AACE) does not yet formally endorse FEI as a clinical standard, but several longevity-medicine practitioners use a FEI of 1.5-4.0 as a functional target in postmenopausal women not on HRT [17].

Practical Lab Ordering and Interpretation

When to Order E1 vs. E2

In premenopausal women, E2 is the clinically dominant estrogen and should be the primary test. E1 becomes the primary estrogen metric in postmenopausal women, particularly those not on estradiol-based HRT. In women on oral estradiol, oral administration converts a large fraction of E2 to E1 during first-pass hepatic metabolism, so E1 rises disproportionately and may not reflect tissue E2 bioavailability. Transdermal estradiol avoids first-pass conversion and produces a more physiologic E2-to-E1 ratio.

The Endocrine Society's 2023 clinical practice guideline on menopausal hormone therapy states: "Serum estradiol is preferred for monitoring therapy; estrone measurements may add value when oral estrogen administration is used, given the significant hepatic conversion of E2 to E1." [17]

Assay Considerations

E1 is best measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS), which has a lower detection limit (typically 1-2 pg/mL) and greater specificity than immunoassays. Many commercial labs still use immunoassay platforms that cross-react with E2 and other steroids, inflating apparent E1 values. When accuracy matters (monitoring HRT or investigating elevated levels), request LC-MS/MS specifically. The reference laboratory ARUP and Quest Diagnostics both offer LC-MS/MS E1 testing.

Timing and Conditions That Distort the Result

Conditions that can falsely lower E1 at the time of the draw include: fasting for more than 12 hours, recent antibiotic use (<6 weeks), acute severe caloric restriction (<500 kcal/day for more than 3 days), and recent intense aerobic exercise (cortisol spike transiently reduces androstenedione). Conditions that may falsely raise E1 include: specimen hemolysis, recent alcohol consumption (within 24 hours), and exogenous estrogen cream applied near the draw site.

Draw E1 in a rested, fed state, at least 6 weeks after any antibiotic course, and at a consistent time of day. Morning draws between 07:00 and 10:00 are standard for most steroid hormones.

Clinical Scenarios Where E1 Nutrition Data Changes Management

Obese Postmenopausal Woman With Elevated E1 and No HRT

A postmenopausal woman with BMI 34, E1 of 155 pg/mL, intact uterus, and no progestogen coverage carries meaningful endometrial proliferation risk despite receiving no prescribed HRT. The source is endogenous adipose aromatization. Per American College of Obstetricians and Gynecologists (ACOG) guidance, unopposed estrogen exposure (whether exogenous or endogenous) in a woman with a uterus warrants discussion of endometrial surveillance [18]. Weight reduction targeting 10-15% total body weight loss would be expected to bring E1 into the 80-100 pg/mL range based on published bariatric and dietary intervention data.

Lean Postmenopausal Woman With E1 Below 20 pg/mL

A lean postmenopausal woman with BMI 21, no HRT, and E1 of 14 pg/mL has minimal adipose aromatase substrate and essentially no ovarian contribution. This patient is likely experiencing significant bone resorption acceleration; DEXA scanning is appropriate. The 2023 Endocrine Society guideline notes that postmenopausal women with symptomatic hypoestrogenism and no contraindications should be offered systemic HRT, and that bone protection benefit is well established for E2 levels above 40 pg/mL [17]. Dietary changes alone will not meaningfully raise E1 in a lean woman with low substrate; HRT evaluation is the correct clinical step.

Woman on Oral Estradiol With Unexpectedly High E1

A patient on oral 17-beta estradiol 1 mg/day with E1 of 280 pg/mL and E2 of 45 pg/mL is showing the classic hepatic first-pass conversion signature. Switching to transdermal estradiol (0.05 mg/day patch) typically normalizes the E1-to-E2 ratio and may reduce total E1 by 40-60% while maintaining or improving E2 [19]. This route-of-administration effect is not a nutritional factor but is a laboratory finding that nutrition-focused providers frequently encounter when reviewing comprehensive hormone panels.